Drug approval is usually a always lengthy approach, but for cannabis there are already the additional hurdles of authorized roadblocks, along with the difficulty in getting patent protections for all-natural compounds.Synthetic cannabinoids (SCs) are a category of compounds equivalent in pharmacological and physiological consequences to tetrahydroc